Skip to main content

Non-Hodgkin's lymphomas, version 2.2014.

Publication ,  Journal Article
Zelenetz, AD; Gordon, LI; Wierda, WG; Abramson, JS; Advani, RH; Andreadis, CB; Bartlett, N; Bellam, N; Byrd, JC; Czuczman, MS; Fayad, LE ...
Published in: J Natl Compr Canc Netw
June 2014

Non-Hodgkin's lymphomas (NHLs) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Follicular lymphoma (FL) is the most common subtype of indolent NHL, accounting for approximately 22% of all newly diagnosed cases of NHL. The incorporation of rituximab to chemotherapy regimens has become a widely accepted standard of care for first-line therapy for patients with FL. Maintenance and consolidation therapy with rituximab and radioimmunotherapy have also been associated with improved progression-free survival in patients experiencing response to first-line therapy. Despite therapeutic advances that have improved outcomes, FL is generally considered a chronic disease characterized by multiple recurrences with current therapies. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with FL.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

June 2014

Volume

12

Issue

6

Start / End Page

916 / 946

Location

United States

Related Subject Headings

  • Rituximab
  • Radioimmunotherapy
  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Lymphoma, Non-Hodgkin
  • Lymphoma, Follicular
  • Humans
  • Disease-Free Survival
  • Antineoplastic Combined Chemotherapy Protocols
  • Antibodies, Monoclonal, Murine-Derived
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., … Sundar, H. (2014). Non-Hodgkin's lymphomas, version 2.2014. J Natl Compr Canc Netw, 12(6), 916–946. https://doi.org/10.6004/jnccn.2014.0086
Zelenetz, Andrew D., Leo I. Gordon, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C Babis Andreadis, Nancy Bartlett, et al. “Non-Hodgkin's lymphomas, version 2.2014.J Natl Compr Canc Netw 12, no. 6 (June 2014): 916–46. https://doi.org/10.6004/jnccn.2014.0086.
Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, et al. Non-Hodgkin's lymphomas, version 2.2014. J Natl Compr Canc Netw. 2014 Jun;12(6):916–46.
Zelenetz, Andrew D., et al. “Non-Hodgkin's lymphomas, version 2.2014.J Natl Compr Canc Netw, vol. 12, no. 6, June 2014, pp. 916–46. Pubmed, doi:10.6004/jnccn.2014.0086.
Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Sokol L, Swinnen LJ, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H. Non-Hodgkin's lymphomas, version 2.2014. J Natl Compr Canc Netw. 2014 Jun;12(6):916–946.

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

June 2014

Volume

12

Issue

6

Start / End Page

916 / 946

Location

United States

Related Subject Headings

  • Rituximab
  • Radioimmunotherapy
  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Lymphoma, Non-Hodgkin
  • Lymphoma, Follicular
  • Humans
  • Disease-Free Survival
  • Antineoplastic Combined Chemotherapy Protocols
  • Antibodies, Monoclonal, Murine-Derived